-transparent.png){kind=logo}
The antineoplastic drug 4'-iodo-4'-deoxydoxorubicin (IDX), a new halogenated anthracycline (1), was examined as a differentiation inducing agent on the human neuroblastoma cell lines TS12 and SK-N-MC. IDX induced morphological and biochemical differentiation and growth inhibition. The effect of a combined treatment of IDX with retinoic acid (RA) and with nerve growth factor (NGF) respectively was then investigated. The responses of neuroblastoma cells to IDX alone and to these combined treatments were compared, with respect to neuritic outgrowth, acetylcholinesterase activity and cellular growth. The data obtained indicate that the combination of differentiation-inducing drugs may be able to enhance the effects of the same drugs given alone.
P Rocchi, and
A M Ferreri, and
G Simone, and
G P Bagnara, and
G Paolucci
January 1992,
Journal of nutritional science and vitaminology,
P Rocchi, and
A M Ferreri, and
G Simone, and
G P Bagnara, and
G Paolucci
November 1988,
Cancer research,
P Rocchi, and
A M Ferreri, and
G Simone, and
G P Bagnara, and
G Paolucci
January 1994,
Progress in clinical and biological research,
P Rocchi, and
A M Ferreri, and
G Simone, and
G P Bagnara, and
G Paolucci
January 1997,
Brain tumor pathology,
P Rocchi, and
A M Ferreri, and
G Simone, and
G P Bagnara, and
G Paolucci
January 1999,
Anticancer research,
P Rocchi, and
A M Ferreri, and
G Simone, and
G P Bagnara, and
G Paolucci
May 2018,
International journal of molecular sciences,
P Rocchi, and
A M Ferreri, and
G Simone, and
G P Bagnara, and
G Paolucci
January 1990,
Acta physiologica Scandinavica. Supplementum,
P Rocchi, and
A M Ferreri, and
G Simone, and
G P Bagnara, and
G Paolucci
January 1988,
Progress in clinical and biological research,
P Rocchi, and
A M Ferreri, and
G Simone, and
G P Bagnara, and
G Paolucci
January 1985,
Progress in clinical and biological research,
P Rocchi, and
A M Ferreri, and
G Simone, and
G P Bagnara, and
G Paolucci
June 1993,
Brain research,
